U.S. Markets open in 2 hrs 4 mins

Enochian Biosciences, Inc. (ENOB)

NasdaqCM - NasdaqCM Delayed Price. Currency in USD
Add to watchlist
1.9300-0.1300 (-6.31%)
At close: 04:00PM EDT
1.9600 +0.03 (+1.55%)
After hours: 07:57PM EDT

Enochian Biosciences, Inc.

Century City Medical Plaza
Suite 906 2080 Century Park East
Los Angeles, CA 90067-2012
United States
305 918 1980

Full Time Employees11

Key Executives

NameTitlePayExercisedYear Born
Dr. Mark R. Dybul M.D.CEO, Director & Member of HBV Scientific Advisory Board430kN/A1964
Ms. Luisa PucheCFO & Corp. Sec.275kN/A1964
Ms. Evelyn D'AnConsultant63.52kN/A1963
Dr. Serhat GümrükcüCo-Founder & InventorN/AN/AN/A
Mr. Tung NguyenHead of Molecular BiologyN/AN/AN/A
Mr. Greg Duczynski Ph.D.Sr. VP for Clinical OperationsN/AN/AN/A
Dr. François Binette M.Sc., Ph.D.Exec. VP for R&DN/AN/AN/A
Dr. Lu Chen Ph.D.Head of Product Devel. & CMCN/AN/AN/A
Amounts are as of December 31, 2021 and compensation values are for the last fiscal year ending on that date. Pay is salary, bonuses, etc. Exercised is the value of options exercised during the fiscal year. Currency in USD.


Enochian Biosciences, Inc., a pre-clinical stage biotechnology company, engages in the research and development of pharmaceutical and biological products for the human treatment of human immunodeficiency virus (HIV), hepatitis B virus (HBV), influenza and coronavirus infections, and cancer. The company's lead candidate includes ENOB-HV-01 for autologous HIV curative treatment; ENOB-HV-11, a preventative HIV vaccine; ENOB-HV-12, a therapeutic HIV vaccine; and ENOB-HB-01, a coopting HBV polymerase. Its pipeline development products comprise ENOB-DC-11 off the shelf DC vaccine for multiple solid tumors; and ENOB-DC-21, a non-specific vaccine for intraturmoral injection. Enochian Biosciences, Inc. has strategic partnerships with The Scripps Institute, Fred Hutchinson Cancer Research Center, the Texas Biomedical Research Institute, the University of California, Los Angeles, and The Hepatitis B Foundation and Baruch S. Blumberg Institute. The company was incorporated in 2017 and is headquartered in Los Angeles, California.

Corporate Governance

Enochian Biosciences, Inc.’s ISS Governance QualityScore as of N/A is N/A. The pillar scores are Audit: N/A; Board: N/A; Shareholder Rights: N/A; Compensation: N/A.

Corporate governance scores courtesy of Institutional Shareholder Services (ISS). Scores indicate decile rank relative to index or region. A decile score of 1 indicates lower governance risk, while a 10 indicates higher governance risk.